ALLMedicine™ Mastocytosis Center

Mar 30th, 2021 - Cutaneous mastocytosis is a rare pathology characterized by an abnormal proliferation and degranulation of mast cells, affecting the skin. Here we present the case of a patient suffering from chronic resistant mastocytosis. An original integrative...

Mar 29th, 2021 - Knowledge on endothelial dysfunction and its relation to atherosclerosis in mastocytosis is limited. To investigate the endothelial function in mastocytosis by flow mediated dilatation (FMD) and biomarkers related to vascular endothelia and to eva...

Mar 27th, 2021 - Imatinib for control of bullous skin lesions in a child with familial mastocytosis.|2021|Kendall J,Martinez A,Bartram J,|

Mar 23rd, 2021 - Clonal mast cell disorders and elevated BST of unknown cause(s) are associated with severe Hymenoptera venom-triggered anaphylaxis (HVA). However, some individuals with clonal disease have normal BST (<11.4 ng/mL). To evaluate whether screening fo...

Mar 18th, 2021 - Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single-cell DNA sequencing.|2021|Lim KH,Wu JN,Huang TY,Jhuang JY,Chang YC,|

Dec 13th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...

Nov 30th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt.

May 19th, 2014 - Mastocytosis is an emerging differential diagnosis in patients with more or less specific mediator-related symptoms. In some of these patients, typical skin lesions are found and the diagnosis of mastocytosis can be established. In other cases, ho...

Mar 30th, 2021 - Cutaneous mastocytosis is a rare pathology characterized by an abnormal proliferation and degranulation of mast cells, affecting the skin. Here we present the case of a patient suffering from chronic resistant mastocytosis. An original integrative...

Mar 29th, 2021 - Knowledge on endothelial dysfunction and its relation to atherosclerosis in mastocytosis is limited. To investigate the endothelial function in mastocytosis by flow mediated dilatation (FMD) and biomarkers related to vascular endothelia and to eva...

Mar 27th, 2021 - Imatinib for control of bullous skin lesions in a child with familial mastocytosis.|2021|Kendall J,Martinez A,Bartram J,|

Mar 23rd, 2021 - Clonal mast cell disorders and elevated BST of unknown cause(s) are associated with severe Hymenoptera venom-triggered anaphylaxis (HVA). However, some individuals with clonal disease have normal BST (<11.4 ng/mL). To evaluate whether screening fo...

Mar 18th, 2021 - Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single-cell DNA sequencing.|2021|Lim KH,Wu JN,Huang TY,Jhuang JY,Chang YC,|

Mar 31st, 2020 - A small-molecule kinase inhibitor that targets a gene mutation complicit in systemic mastocytosis has been found to reduce symptoms by about 30%, according to early results of a clinical trial scheduled to be presented at the American Academy of A.

Jul 9th, 2019 - However, the Expert Committee still did not define either the length of time of flushing or nontransient erythema. It also did not specify convex surfaces of the face with periocular sparing as the characteristic pattern or provide additional info.

Dec 8th, 2018 - Photo by Jen Smith Jason R. Gotlib, MD SAN DIEGO—The KIT D816V inhibitor avapritinib can improve symptoms of systemic mastocytosis (SM), according to researchers.

Sep 14th, 2018 - Introduction: Systemic mastocytosis (SM) is a rare myeloid neoplasm that is caused by accumulation of abnormal mast cells in the bone marrow, liver, spleen, and skin. The KIT D816V mutation encodes a constitutively activated receptor tyrosine kina.

Jun 25th, 2018 - Photo from EHA Poster session at the 23rd Congress of the European Hematology Association (EHA) STOCKHOLM—The KIT/PDGFRA inhibitor avapritinib has produced durable responses in patients with systemic mastocytosis (SM). In the phase 1 EXPLORER tria.